This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1(+) BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFNα2a to IM600 is feasible, and able to overcome resistance within this context.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.leukres.2010.04.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of N-acetylcysteine in reducing inflammation and oxidative stress to prevent complex regional pain syndrome type 1.
Medicine (Baltimore)
September 2024
Bursa City Hospital, Orthopedics and Traumatology Clinics, Bursa, Turkey.
This study aimed to evaluate the effectiveness of N-acetylcysteine (NAC) in preventing complex regional pain syndrome type 1 (CRPS-1) by reducing proinflammatory cytokines and oxidative stress markers in patients with distal radius fractures. A retrospective single-center study at Bursa City Hospital involves patients over 50 years of age with distal radius fractures treated between January 2021 and December 2023. A total of 60 patients (mean age, 62.
View Article and Find Full Text PDFEffectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
Clin Infect Dis
December 2024
iDFFEAT TB Project, International Union Against Tuberculosis and Lung Disease, New Delhi, India.
Article Synopsis
- The study examined the effectiveness and safety of reducing linezolid doses in a treatment regimen for adults with pre-extensively drug-resistant or treatment-intolerant multidrug-resistant tuberculosis.
- Patients were enrolled in a clinical trial where they were randomly assigned to three different dosing regimens of linezolid, alongside bedaquiline and pretomanid, for a total duration of 26 weeks.
- Results showed that the reduced dose of linezolid (300 mg/day) maintained similar cure rates as the standard dose (600 mg/day) while leading to fewer reported cases of peripheral neuropathy, suggesting a safer approach for treating this condition.
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.
BioDrugs
September 2024
Department of Dermatology, Peking University People's Hospital, No. 11, Xizhimen South Street, Beijing, 100044, China.
Background: Stapokibart/CM310, a humanized monoclonal antibody targeting the interleukin-4 receptor α chain, has shown promising treatment benefits in patients with moderate-to-severe atopic dermatitis in previous phase II clinical trials.
Objective: We aimed to evaluate the long-term efficacy and safety of stapokibart in adults with moderate-to-severe atopic dermatitis.
Methods: Enrolled patients who previously completed parent trials of stapokibart received a subcutaneous stapokibart 600-mg loading dose, then 300 mg every 2 weeks up to 52 weeks.
Clinical study of 400mg efavirenz treatment in newly diagnosed patients with HIV/AIDS.
Pak J Pharm Sci
March 2024
Department of Infection, Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan, China.
Article Synopsis
- - The study compares the effectiveness and side effects of 400mg and 600mg efavirenz (EFV) in treating HIV-infected patients, concluding that both dosages provide similar antiviral efficacy.
- - A total of 50 patients were divided into two groups receiving either 3TC+TDF+400mg EFV or 3TC+TDF+600mg EFV, with both groups showing HIV inhibition rates of 56.52% at week 24 and nearly full efficacy at week 48.
- - Patients on the 400mg EFV experienced significantly fewer adverse effects, with only 27 reported cases compared to 39 in the 600mg group, particularly reporting lower rates of transamin
[Clinical Efficacy and Safety of Flumatinib in the Treatment of Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
February 2024
Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.E-mail:
Objective: To explore the clinical efficacy and safety of flumatinib mesylate produced in China in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
Methods: 32 newly diagnosed CML-CP patients admitted to the Hematology Department of the Affiliated Hospital of Southwest Medical University from March 1, 2020 to March 31, 2022, who had never received any tyrosine kinase inhibitor (TKI) were included in the study. The patients were treated by flumatinib mesylate 600mg once daily.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!